Benjamin P Martin
Overview
Explore the profile of Benjamin P Martin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
499
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sarrazin M, Martin B, Avellan R, Gnawali G, Poncin I, Le Guenno H, et al.
ACS Infect Dis
. 2022 Nov;
8(12):2564-2578.
PMID: 36379042
Patients with cystic fibrosis (CF) have a significantly higher risk of acquiring nontuberculous mycobacteria infections, predominantly due to , than the healthy population. Because infections are a major cause of...
2.
Subramaniam T, Martin B, Jester I, Soccorso G, Pachl M, Robb A, et al.
J Pediatr Surg
. 2022 Jun;
57(11):516-519.
PMID: 35690479
Aim: Thoracoscopically placed internal traction sutures (ITS) for the initial management of long gap oesophageal atresia (LGOA), not amenable to primary anastomosis, was first described in 2015. Here we describe...
3.
Costacurta M, Vervoort S, Hogg S, Martin B, Johnstone R, Shortt J
Haematologica
. 2020 Dec;
106(7):2013-2017.
PMID: 33375771
Not available.
4.
Madani A, Ridenour J, Martin B, Paudel R, Abdul Basir A, Le Moigne V, et al.
ACS Infect Dis
. 2019 Jul;
5(9):1597-1608.
PMID: 31299146
Twelve new Cyclophostin and Cyclipostins analogues () were synthesized, thus extending our series to 38 . Their antibacterial activities were evaluated against four pathogenic mycobacteria (, , BCG, and )...
5.
Nguyen P, Nguyen V, Martin B, Fourquet P, Camoin L, Spilling C, et al.
J Mol Biol
. 2018 Oct;
430(24):5120-5136.
PMID: 30292819
With the high number of patients infected by tuberculosis and the sharp increase of drug-resistant tuberculosis cases, developing new drugs to fight this disease has become increasingly urgent. In this...
6.
Nguyen P, Madani A, Santucci P, Martin B, Paudel R, Delattre S, et al.
Int J Antimicrob Agents
. 2017 Dec;
51(4):651-654.
PMID: 29241819
The progression of mycobacterial diseases requires the development of new therapeutics. This study evaluated the efficacy and selectivity of a panel of Cyclophostin and Cyclipostins analogues (CyCs) against various bacteria...
7.
Nguyen P, Delorme V, Benarouche A, Martin B, Paudel R, Gnawali G, et al.
Sci Rep
. 2017 Sep;
7(1):11751.
PMID: 28924204
A new class of Cyclophostin and Cyclipostins (CyC) analogs have been investigated against Mycobacterium tuberculosis H37Rv (M. tb) grown either in broth medium or inside macrophages. Our compounds displayed a...
8.
Lefebure M, Tothill R, Kruse E, Hawkins E, Shortt J, Matthews G, et al.
Nat Commun
. 2017 Mar;
8:14581.
PMID: 28262675
The Eμ-Myc mouse is an extensively used model of MYC driven malignancy; however to date there has only been partial characterization of MYC co-operative mutations leading to spontaneous lymphomagenesis. Here...
9.
Hogg S, Vervoort S, Deswal S, Ott C, Li J, Cluse L, et al.
Cell Rep
. 2017 Mar;
18(9):2162-2174.
PMID: 28249162
BET inhibitors (BETi) target bromodomain-containing proteins and are currently being evaluated as anti-cancer agents. We find that maximal therapeutic effects of BETi in a Myc-driven B cell lymphoma model required...
10.
Hogg S, Newbold A, Vervoort S, Cluse L, Martin B, Gregory G, et al.
Mol Cancer Ther
. 2016 Jul;
15(9):2030-41.
PMID: 27406984
Targeting BET bromodomain proteins using small molecules is an emerging anticancer strategy with clinical evaluation of at least six inhibitors now underway. Although MYC downregulation was initially proposed as a...